MSD Animal Health has launched a new intradermal vaccine in Great Britain that it says will make it easier to protect piglets from four major diseases in just one intradermal vaccination event.
PORCILIS PCV M Hyo ID protects against two of the most common pig diseases, while offering animal-friendly and efficient administration through IDAL device technology, the company said.
The ready-to-use intradermal vaccine offers protection against two of the most common pig pathogens, Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae (M. hyo), and ‘represents an important step forward for practical pig vaccination’, MSD said.
The company said it offers vaccination programme flexibility for producers as it is compatible for mixing with PORCILIS LAWSONIA ID, and can be co-administered on the same day – but not mixed – with PORCILIS PRRS, meaning piglets can be protected against four key diseases within a single administration using the IDAL Twin device.
“Not only does this make protecting pigs from endemic challenges simpler for farmers and vets, but administration through the IDAL device also offers key animal welfare benefits, including less pain and stress for pigs, reduced risk for iatrogenic transmission of pathogens between pigs, reduced tissue damage and no risk of broken needles,” MSD said.
The innovative vaccine was formulated by combining M. hyo, and PCV2 in a single low volume dose (0.2 ml), and can be administered to pigs from three weeks of age, including pregnant and lactating sows.
“Pig producers are operating within an intense and fast-moving environment thanks to tighter margins, workforce shortages and rising welfare expectations so they need animal health solutions that are practical and effcacious,” said Dr Serena Shanahan, veterinary technical manager at MSD Animal Health.
“We are therefore excited to be expanding our trusted PORCILIS® ID range to further support producers and their vets. PORCILIS PCV M Hyo ID makes it easier than ever for pig producers to protect their animals against four major diseases with just one, simple, needle-free intervention. This enables vets and producers to streamline protocols saving time and effort whilst maintaining efficacy.”
Concurrent infection
MSD pointed out that the diseases caused by PCV2 and M. hyo are associated with increased morbidity and mortality in piglet populations, meaning concurrent infection with both can cause severe respiratory disease and lung lesions as well as weight loss during the finishing period.
“PORCILIS PCV M Hyo ID allows farmers to vaccinate piglets against both infectious agents at once, while also providing efficiency, convenience and flexibility. Intradermal vaccines also provide sustainability benefits due to less packaging, waste and transport and lower cold chain volume requirements,” Dr Shanahan added.
“This innovative vaccine is an important step forward for practical piglet vaccination, strengthens our intradermal range and demonstrates MSD Animal Health’s commitment to pioneering science and technology solutions that are shaping the future of animal health.”
With Veterinary Medicines Directorate approval received in October 2025, PORCILIS PCV M Hyo ID is now the fifth pig vaccine in Great Britain from MSD Animal Health that is administered through intradermal, needle-free application with IDAL technology.